Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048583639> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3048583639 abstract "Apremilast is the first small molecule approved for the treatment of moderate to severe psoriasis and psoriatic arthritis in adult patients. To evaluate survival, efficacy and safety of apremilast in patients with moderate to severe psoriasis and investigate possible associations between apremilast survival and clinical parameters in a real-world setting. In this retrospective study, a total of 71 patients who started on apremilast treatment between March 2017 and December 2019 were identified and included in the study: 40 (56.3%) males and 31 (43.7%) females, with a mean age of 55.6 ± 13.8 years and a mean Body Mass Index of 28.4 ± 6.9 kg/m2. At the end of the study 49.3% of patients remained on apremilast with mean treatment duration 67.2 ± 41.1 weeks (range 4-132). Overall, mean drug survival duration was 78.51 weeks (95% CI: 65.8-91.2 weeks). Mean drug survival was shorter when comorbidities burden was higher (P = .012) and with previous exposure of biological agents (P = .001). Previous exposure to biological agents (HR:3.86, 95% CI: 1.35-11.04, P = .012) and comorbidities burden (HR: 2.27, 95% CI: 1.25-4.12, P = .007) were independent predictors of drug discontinuation adjusting for important clinical parameters. In this real-world setting, apremilast presented better survival rates when introduced early on the onset of moderate psoriasis, especially in biologic naïve patients with less comorbidities. More prospective and larger studies are required to determine clinical parameters affecting drug survival." @default.
- W3048583639 created "2020-08-18" @default.
- W3048583639 creator A5016870178 @default.
- W3048583639 creator A5027685440 @default.
- W3048583639 creator A5067165268 @default.
- W3048583639 date "2020-09-13" @default.
- W3048583639 modified "2023-10-10" @default.
- W3048583639 title "Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real‐world setting" @default.
- W3048583639 cites W2761544020 @default.
- W3048583639 cites W2789500270 @default.
- W3048583639 cites W2791244279 @default.
- W3048583639 cites W2799813944 @default.
- W3048583639 cites W3016827384 @default.
- W3048583639 cites W3021905655 @default.
- W3048583639 cites W3030782004 @default.
- W3048583639 cites W3036864566 @default.
- W3048583639 doi "https://doi.org/10.1111/dth.14168" @default.
- W3048583639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32779293" @default.
- W3048583639 hasPublicationYear "2020" @default.
- W3048583639 type Work @default.
- W3048583639 sameAs 3048583639 @default.
- W3048583639 citedByCount "9" @default.
- W3048583639 countsByYear W30485836392021 @default.
- W3048583639 countsByYear W30485836392022 @default.
- W3048583639 countsByYear W30485836392023 @default.
- W3048583639 crossrefType "journal-article" @default.
- W3048583639 hasAuthorship W3048583639A5016870178 @default.
- W3048583639 hasAuthorship W3048583639A5027685440 @default.
- W3048583639 hasAuthorship W3048583639A5067165268 @default.
- W3048583639 hasBestOaLocation W30485836391 @default.
- W3048583639 hasConcept C126322002 @default.
- W3048583639 hasConcept C16005928 @default.
- W3048583639 hasConcept C2776260265 @default.
- W3048583639 hasConcept C2776364478 @default.
- W3048583639 hasConcept C2778715236 @default.
- W3048583639 hasConcept C2779609412 @default.
- W3048583639 hasConcept C2780035454 @default.
- W3048583639 hasConcept C2780564577 @default.
- W3048583639 hasConcept C2781427535 @default.
- W3048583639 hasConcept C71924100 @default.
- W3048583639 hasConcept C98274493 @default.
- W3048583639 hasConceptScore W3048583639C126322002 @default.
- W3048583639 hasConceptScore W3048583639C16005928 @default.
- W3048583639 hasConceptScore W3048583639C2776260265 @default.
- W3048583639 hasConceptScore W3048583639C2776364478 @default.
- W3048583639 hasConceptScore W3048583639C2778715236 @default.
- W3048583639 hasConceptScore W3048583639C2779609412 @default.
- W3048583639 hasConceptScore W3048583639C2780035454 @default.
- W3048583639 hasConceptScore W3048583639C2780564577 @default.
- W3048583639 hasConceptScore W3048583639C2781427535 @default.
- W3048583639 hasConceptScore W3048583639C71924100 @default.
- W3048583639 hasConceptScore W3048583639C98274493 @default.
- W3048583639 hasIssue "6" @default.
- W3048583639 hasLocation W30485836391 @default.
- W3048583639 hasOpenAccess W3048583639 @default.
- W3048583639 hasPrimaryLocation W30485836391 @default.
- W3048583639 hasRelatedWork W1964002779 @default.
- W3048583639 hasRelatedWork W2003939908 @default.
- W3048583639 hasRelatedWork W2034115370 @default.
- W3048583639 hasRelatedWork W2152630501 @default.
- W3048583639 hasRelatedWork W2329628791 @default.
- W3048583639 hasRelatedWork W2407870820 @default.
- W3048583639 hasRelatedWork W2995422082 @default.
- W3048583639 hasRelatedWork W3100915479 @default.
- W3048583639 hasRelatedWork W4252588308 @default.
- W3048583639 hasRelatedWork W4317932061 @default.
- W3048583639 hasVolume "33" @default.
- W3048583639 isParatext "false" @default.
- W3048583639 isRetracted "false" @default.
- W3048583639 magId "3048583639" @default.
- W3048583639 workType "article" @default.